PEPG trades 168.3% below Wall Street's consensus target of $5.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PEPG achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, PepGen Inc. (PEPG) has a Wall Street consensus price target of $5.50, based on estimates from 6 covering analysts. With the stock currently trading at $2.05, this represents a potential upside of +168.3%. The company has a market capitalization of $142M.
Analyst price targets range from a low of $4.00 to a high of $7.00, representing a 55% spread in expectations. The median target of $5.50 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, PEPG trades at a trailing P/E of -1.0x. Analysts expect EPS to grow +39.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
SRPTSarepta Therapeutics, Inc. | $2.1B | $19.79 | $25.14 | +27.0% | Buy | 5.6x | 54 |
FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
RAREUltragenyx Pharmaceutical Inc. | $3.5B | $35.87 | $47.11 | +31.3% | Buy | — | 33 |
CRSPCRISPR Therapeutics AG | $5.9B | $60.77 | $71.67 | +17.9% | Buy | — | 38 |
EDITEditas Medicine, Inc. | $367M | $3.75 | $5.00 | +33.3% | Buy | — | 25 |
NTLAIntellia Therapeutics, Inc. | $2.0B | $17.43 | $26.13 | +49.9% | Buy | — | 39 |
IONSIonis Pharmaceuticals, Inc. | $14.3B | $86.33 | $106.50 | +23.4% | Buy | — | 32 |
ALNYAlnylam Pharmaceuticals, Inc. | $42.9B | $321.59 | $450.64 | +40.1% | Buy | 43.2x | 52 |
ARWRArrowhead Pharmaceuticals, Inc. | $12.3B | $86.97 | $91.00 | +4.6% | Buy | — | 21 |
WAVEEco Wave Power Global AB (publ) | $53M | $9.07 | — | — | — | — | — |
Quick answers to the most common questions about buying PEPG stock.
The consensus Wall Street price target for PEPG is $5.5, representing 168.3% upside from the current price of $2.05. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PEPG has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $5.5 implies 168.3% upside from current levels.
PEPG's current price is $2.05 with a consensus target of $5.5 (168.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $7 for PEPG, while the most conservative target is $4. The consensus of $5.5 represents the median expectation. These targets typically reflect 12-month expectations.
PEPG is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PEPG stock forecast based on 6 Wall Street analysts shows a consensus price target of $5.5, with estimates ranging from $4 (bear case) to $7 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on PEPG, with a "Buy" consensus rating and $5.5 price target (168.3% upside). 5 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PEPG analyst price targets range from $4 to $7, a 55% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.